Genentech Executive Jason Ehrlich Joins Kodiak Sciences C-Suite
Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients who have the “wet” form of age-related macular degeneration.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX
From Our Advertisers
Wisconsin helps biotech company raise $20 million
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation